Deal Watch: Roche Terminates Gene Therapy Alliance, Partners In IBD With Synlogic
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.
You may also be interested in...
The antiplatelet drug-reversal agent could see uptake grow in tandem with that of Brilinta, but there is a history of drugs in similar indications underperforming on the market.
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
EQRx has raised at least $750m since it launched in January 2020 and will have $2bn to fund its ongoing development of low-cost drugs after merging with a special purpose acquisition corporation.